TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8341512

Group type: EXPERIMENTAL
Intervention: Diode laser trabeculoplasty (DLT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 25
Study: 3538985

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sham TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 31736342

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13195

Group type: COMPARATOR
Intervention: Renin-angiotensin-aldosterone-system inhibitor
Number of subjects: 13195
Study: 30522438

Group type: EXPERIMENTAL
Intervention: Progressively autonomous physical activity (PAPA) program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard supervised physical activity (SPA) program
Number of subjects: 50
Study: 24267148

Group type: EXPERIMENTAL
Intervention: Oral iron
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 30
Study: 23161038

Group type: EXPERIMENTAL
Intervention: L-arginine (2 g tid or 4 g tid)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20123315

Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg intravenously daily for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 18308809

Group type: EXPERIMENTAL
Intervention: High-dose ATD
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose ATD
Number of subjects: 18
Study: 16610475

Group type: EXPERIMENTAL
Intervention: Multimedia stories about American deaf celebrities
Number of subjects: 0
Study: 12036724

Group type: EXPERIMENTAL
Intervention: HPMC capsules (oral administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HPMC capsules (rectal administration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gelatine capsules (oral administration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gelatine capsules (rectal administration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HPMC capsules (various viscosity grades)
Number of subjects: 16
Study: 10520777

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (lepirudin, i.v. bolus of 0.2 mg/kg, followed by s.c. injections of 0.5 mg/kg b.i.d. for 5 to 7 days)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (lepirudin)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Heparin (i.v. placebo bolus, followed by s.c. injections of 12,500 IU b.i.d. for 5 to 7 days)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1208
Study: 7872337

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg immediately and twice daily thereafter (outpatient management)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg immediately and twice daily thereafter (inpatient management)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 182

Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 182
Study: 2779095

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice a day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gemfibrozil plus colestipol 10 grams twice a day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 64482

Group type: EXPERIMENTAL
Intervention: Skin testing with dialyzed Hymenoptera venoms (HDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skin testing with whole body diagnostic allergenic extract
Number of subjects: 0
Study: 31570942

Group type: EXPERIMENTAL
Intervention: Diversion group (blood drawn into lithium heparin tube before blood culture bottles)
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control group (blood cultures first, then lithium heparin tube)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Diversion group
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 970
Study: 31319192

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.7mcg/kg/h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 19
Study: 27883209

Group type: EXPERIMENTAL
Intervention: Tongue-to-palate resistance training (TPRT) for 4 weeks (5 days per week) plus traditional dysphagia therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional dysphagia therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TPRT plus traditional dysphagia therapy
Number of subjects: 35
Study: 25733634

Group type: EXPERIMENTAL
Intervention: Protein diets (5%, 15%, or 25%)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-protein diet group (excess energy from fat)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All 3 groups (over 8 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-protein diet group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Days 1, 14, and 56
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Excess energy as protein
Number of subjects: 25

Group type: COMPARATOR
Intervention: Change in fat mass
Number of subjects: 25
Study: 23228340

Group type: EXPERIMENTAL
Intervention: Escitalopram plus placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release plus escitalopram
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release plus mirtazapine
Number of subjects: 665
Study: 21800009

Group type: EXPERIMENTAL
Intervention: 75 mg aspirin BID
Number of subjects: 25

Group type: COMPARATOR
Intervention: 320 mg aspirin OD
Number of subjects: 25
Study: 19380597

Group type: EXPERIMENTAL
Intervention: Pagibaximab (10, 30, 60, or 90 mg/kg of body weight)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 16271272

Group type: EXPERIMENTAL
Intervention: Regimen I: oral praziquantel (40 mg/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regimen II: oral ivermectin (200 microg/kg body weight) with oral albendazole (400 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Regimen III: oral ivermectin with oral albendazole and praziquantel
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Concurrent administration of all three drugs (albendazole, praziquantel, ivermectin)
Number of subjects: 23
Study: 15081078

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 227

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 227
Study: 11062573

Group type: EXPERIMENTAL
Intervention: Centro-central union (CCU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple transection of the digital nerves (control)
Number of subjects: 60
Study: 9052592

Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol orally every 4 hours as needed
Number of subjects: 275

Group type: COMPARATOR
Intervention: Treatment according to established protocol (physician‐chosen combinations of intracervical or vaginal prostaglandins every 4‐6 hours, artificial rupture of membranes, and oxytocin infusion)
Number of subjects: 275
Study: 8498881

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg three times daily from menstrual cycle day 16
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.50 mg three times daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.75 mg three times daily from menstrual cycle day 16
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 22
Study: 3687519

Group type: EXPERIMENTAL
Intervention: BBC TV series 'So You Want To Stop Smoking?'
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control film of the same length
Number of subjects: 134
Study: 30255720

Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (0.015 mg/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (0.03 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27555183

Group type: EXPERIMENTAL
Intervention: Lightwand-guided insertion technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard insertion technique
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 300
Study: 24506827

Group type: EXPERIMENTAL
Intervention: Mandibular second premolar infiltration (SP) with 4% articaine and 1:100,000 adrenaline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mandibular first molar infiltration (FM) with 4% articaine and 1:100,000 adrenaline
Number of subjects: 29
Study: 21492884

Group type: EXPERIMENTAL
Intervention: Cinacalcet 60 mg single dose
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 35
Study: 21036880

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg bid) combined with TACE (doxorubicin 50 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg bid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg bid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sorafenib combined with TACE
Number of subjects: 14
Study: 18408077

Group type: EXPERIMENTAL
Intervention: Renilon 7.5(R) oral supplement, 2 packs of 125-ml daily for 3 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (CTRL)
Number of subjects: 86
Study: 15936131

Group type: EXPERIMENTAL
Intervention: Swanson metacarpophalangeal implants
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sutter metacarpophalangeal implants
Number of subjects: 215
Study: 14651229

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 60
Study: 10424367

Group type: EXPERIMENTAL
Intervention: 3,000 IU aXa of certoparin
Number of subjects: 341

Group type: COMPARATOR
Intervention: 5,000 IU aXa of certoparin
Number of subjects: 341
Study: 8763801

Group type: EXPERIMENTAL
Intervention: MOS SF-36 questionnaire
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison with South Australian elderly general population
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison with groups of Australian subjects with various medical and psychiatric conditions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison with elderly Adelaide residents from a household survey
Number of subjects: 60
Study: 1803828

Group type: EXPERIMENTAL
Intervention: Danazol 600 mg/daily for 3 months plus local immunosuppressive treatment combined with superovulation and IPI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danazol for 3 months plus superovulation and IPI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Superovulation and IPI
Number of subjects: 0
Study: 6819028

Group type: EXPERIMENTAL
Intervention: Protein energy supplementation (energy and vitamins with 5-11% of energy from milk protein)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Energy supplementation (42-80 MJ; 10,000-19,000 kcal/trimester, all from carbohydrate, plus vitamins)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vitamin-only supplementation (vitamin C 30 mg daily, iron 3 mg daily)
Number of subjects: 153
Study: 31706911

Group type: EXPERIMENTAL
Intervention: Cross-match compatible platelets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Uncross-matched platelets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Incompatible platelets
Number of subjects: 38
Study: 30363663

Group type: EXPERIMENTAL
Intervention: Community-Based Continuous Training (CBCT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27297611

Group type: EXPERIMENTAL
Intervention: Dynamic Optimal Timing (DOT) method
Number of subjects: 995
Study: 25461789

Group type: EXPERIMENTAL
Intervention: Computer-Based Training for Cognitive Behavioral Therapy (CBT4CBT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: WAI‐Tech
Number of subjects: 66
Study: 21366709

Group type: EXPERIMENTAL
Intervention: Single ALA‐PDT illumination (75 J/cm², 2 sessions 7 days apart)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fractionated ALA‐PDT illumination (20 J/cm² and 80 J/cm², 4 and 6 hours after a single ALA application)
Number of subjects: 33
Study: 19681533

Group type: EXPERIMENTAL
Intervention: Concept-based learning activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nursing clinical education model (control group)
Number of subjects: 0
Study: 17210046

Group type: EXPERIMENTAL
Intervention: Care from an allergy-trained primary healthcare professional
Number of subjects: 202

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 202
Study: 15570521

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 93
Study: 11443537

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) immunotherapy
Number of subjects: 18
Study: 9930401

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (0.8 g x 3 capsules/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FOE) supplementation (0.8 g x 3 capsules/d with 3 IU/g vitamin E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (FOE) supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) and Fish oil with vitamin E (FOE) supplementation
Number of subjects: 30
Study: 7809530

Group type: EXPERIMENTAL
Intervention: Neomycin (2g/day for 10 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2837262

Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-pulsatile cardiopulmonary bypass
Number of subjects: 20
Study: 31948337

Group type: EXPERIMENTAL
Intervention: Breakfast meal with 9 g fat and 25 g sugar
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Breakfast meal with 28 g fat and 18 g sugar
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Breakfast meal with 5 g fat and 56 g sugar
Number of subjects: 25
Study: 28893130

Group type: EXPERIMENTAL
Intervention: Boost (40% hydrogen peroxide)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dash (30% hydrogen peroxide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bite&White (6% hydrogen peroxide)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boost group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dash group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bite&White treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 30
Study: 26867667

Group type: EXPERIMENTAL
Intervention: Third molar retention during ORIF
Number of subjects: 64

Group type: COMPARATOR
Intervention: Third molar removal during ORIF
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Third molar retention and removal during ORIF
Number of subjects: 64
Study: 26541501

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy delivered in Spanish (MET‐S)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy delivered in English (MET‐E)
Number of subjects: 866
Study: 24345073

Group type: EXPERIMENTAL
Intervention: Geriatric physiotherapy according to the Coach2Move strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coach2Move intervention
Number of subjects: 0
Study: 21483217

Group type: EXPERIMENTAL
Intervention: First repeated public release (August 29, 2005)
Number of subjects: 1951303

Group type: COMPARATOR
Intervention: Baseline cesarean section rates
Number of subjects: 1951303

Group type: COMPARATOR
Intervention: Annual number of deliveries
Number of subjects: 1951303
Study: 18300985

Group type: EXPERIMENTAL
Intervention: Ketorolac and bupivacaine (30 mg and 150 mg, respectively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 17030772

Group type: EXPERIMENTAL
Intervention: Self-administered ALSFRS-R
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard evaluator-administered ALSFRS-R
Number of subjects: 60
Study: 12728215

Group type: EXPERIMENTAL
Intervention: Formulated soy stanols (1.9 g) in a lemonade-flavored beverage
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Formulated soy stanols (1.9 g) in egg whites
Number of subjects: 45
Study: 10789595

Group type: EXPERIMENTAL
Intervention: Doxil 60 mg/m2 every 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Doxil 45 mg/m2 every 3 weeks
Number of subjects: 15
Study: 9162611

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 40
Study: 1637574

Group type: EXPERIMENTAL
Intervention: Intravenous salcatonin (100 U/d, continuous infusion for five days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular salcatonin (100 U/d, single bolus for five days)
Number of subjects: 20
Study: 6425913

Group type: EXPERIMENTAL
Intervention: 10 mg d‐amphetamine
Number of subjects: 5

Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lower doses of d‐amphetamine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30826599

Group type: EXPERIMENTAL
Intervention: CocoaCHOC (chocolate milk with additional cocoa flavanols)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHOC (chocolate milk)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CocoaCHOC
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHOC
Number of subjects: 13
Study: 29544910

Group type: EXPERIMENTAL
Intervention: Busy day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rest day
Number of subjects: 50
Study: 27299809

Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg
Number of subjects: 3856

Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg
Number of subjects: 3856

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3856

Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 4 weeks (after week 12 reassignment)
Number of subjects: 3856

Group type: EXPERIMENTAL
Intervention: 80 mg of ixekizumab every 12 weeks (after week 12 reassignment)
Number of subjects: 3856

Group type: COMPARATOR
Intervention: Placebo (after week 12 reassignment)
Number of subjects: 3856

Group type: EXPERIMENTAL
Intervention: Continuous treatment of ixekizumab from weeks 0 through 60
Number of subjects: 3856
Study: 24521364

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Stretching and strengthening group
Number of subjects: 179
Study: 23190503

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients who accepted randomization
Number of subjects: 24

Group type: COMPARATOR
Intervention: Qualitative interviews with patients who declined randomization
Number of subjects: 24
Study: 20436049

Group type: EXPERIMENTAL
Intervention: Non-compliance with non-pharmacological recommendations (diet, fluid restriction, weighing, exercise)
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Non-compliance with exercise
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Non-compliance with daily weighing
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Non-compliance overall
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Overall non-compliance or with weighing and exercise
Number of subjects: 830
Study: 18589034

Group type: EXPERIMENTAL
Intervention: Liquid meal replacement product
Number of subjects: 24

Group type: COMPARATOR
Intervention: Solid meal replacement product
Number of subjects: 24
Study: 16290981

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 72
Study: 11932310

Group type: EXPERIMENTAL
Intervention: GH treatment for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GH treatment for 12 months
Number of subjects: 10
Study: 9839822

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Beliefs about pain etiology (cancer vs. non-cancer)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 32
Study: 8535040

Group type: EXPERIMENTAL
Intervention: Comparative blocks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparative blocks (expanded criteria)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo-controlled blocks
Number of subjects: 50
Study: 2122026

Group type: EXPERIMENTAL
Intervention: IVPB method (gentamicin mixed in 5% dextrose in water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ILB method (gentamicin mixed using total nutrient admixture solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of IVPB and ILB methods
Number of subjects: 0
Study: 97711

Group type: EXPERIMENTAL
Intervention: Lithium chloride 16 mmol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lithium chloride 32 mmol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo sodium chloride 32 mmol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lithium chloride 16 mmol (chronic)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo sodium chloride (chronic)
Number of subjects: 12
Study: 29712630

Group type: EXPERIMENTAL
Intervention: Immediate group (received intervention immediately)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Delayed group (received intervention after 2 months)
Number of subjects: 61
Study: 28905221

Group type: EXPERIMENTAL
Intervention: Percutaneous reduction
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 49
Study: 26217065

Group type: EXPERIMENTAL
Intervention: BMAC infusion in NIHF group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BMAC infusion in IHF group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (standard heart failure care) in IHF group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (standard heart failure care) in NIHF group
Number of subjects: 60
Study: 23787916

Group type: EXPERIMENTAL
Intervention: ipilimumab/dacarbazine (DTIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo/dacarbazine (DTIC)
Number of subjects: 0